Observational Study comparing Anti-CGRP mABs to OnabotulinumtoxinA for #chronicmigraine

Transcript 👇

A new study from the Journal of Headache and Pain takes a look at the real-world effectiveness of Anti-CGRP monoclonal antibodies and OnabotulinumtoxinA for people with chronic migraine.

Researchers found that while both types of drugs were effective, the anti-CGRP drugs have a slight edge on effectiveness. Here’s what they found…

At 12 months, people using Anti-CGRP monoclonal antibodies saw a drop of 11.9 monthly headache days while those using onabotulinumtoxinA saw a drop in 7.6 days.

People using Anti-CGRP drugs also had a higher reduction in migraine-related disability scores, and a bigger drop in the amount of acute migraine drugs used each month – compared to those who used onabotulinumtoxinA. The results of this study come from observation of 183 patients. However, eptinezumab was not included in this study.